Literature DB >> 8964702

[Epidemiology of varicella zoster infection. Results of a prospective study in the Ansbach area].

E Paul1, T Thiel.   

Abstract

In the country city of Ansbach, Germany all cases of varicellazoster virus infection seen by dermatologists, pediatricians and general practitioners were registered over a period of 16 months, from February 1992 until May 1993. 152 patients were clinically diagnosed with herpes zoster and 437 patients with chickenpox. The population-based incidence of zoster infections was 22.6 per 10,000 inhabitants per year, while the incidence of chickenpox was 42.4. There was a slight predominance of male patients with zoster. There was also a marked influence of age and sex, on the localization of the involved nerve segments. Zoster was seen in patients of all ages but there was a clear predominance in older patients. The peak of the disease occurred in the eighth decade. In patients with chickenpox, the sex ratio was equal. The disease typically occurs in children and we observed a predominance of the cases in the first decade. Spread over the year, zoster was seen equally during all seasons. Chickenpox, however, showed epidemiological peaks of frequency. It is possible that the epidemic spread of the disease and the end of the peak are influenced by special metereological conditions.

Entities:  

Mesh:

Year:  1996        PMID: 8964702     DOI: 10.1007/s001050050476

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  11 in total

1.  Impact of herpes zoster and post-herpetic neuralgia on patients' quality of life: a patient-reported outcomes survey.

Authors:  Thomas Weinke; Alexander Edte; Sonja Schmitt; Kati Lukas
Journal:  Z Gesundh Wiss       Date:  2010-03-21

2.  The impact of herpes zoster and post-herpetic neuralgia on quality-of-life.

Authors:  Robert W Johnson; Didier Bouhassira; George Kassianos; Alain Leplège; Kenneth E Schmader; Thomas Weinke
Journal:  BMC Med       Date:  2010-06-21       Impact factor: 8.775

3.  Herpes zoster in Germany: quantifying the burden of disease.

Authors:  Bernhard Ultsch; Anette Siedler; Thorsten Rieck; Thomas Reinhold; Gérard Krause; Ole Wichmann
Journal:  BMC Infect Dis       Date:  2011-06-16       Impact factor: 3.090

4.  Epidemiology and cost of herpes zoster and postherpetic neuralgia in Germany.

Authors:  Bernhard Ultsch; Ingrid Köster; Thomas Reinhold; Anette Siedler; Gérard Krause; Andrea Icks; Ingrid Schubert; Ole Wichmann
Journal:  Eur J Health Econ       Date:  2012-12-28

5.  A Case of Ramsay Hunt Syndrome with Atypical Presentation.

Authors:  Kamil Kayayurt; Ozcan Yavasi; Ozlem Bilir; Gokhan Ersunan; Baris Giakoup
Journal:  Turk J Emerg Med       Date:  2016-02-26

6.  Estimation of the burden of varicella in Europe before the introduction of universal childhood immunization.

Authors:  Margarita Riera-Montes; Kaatje Bollaerts; Ulrich Heininger; Niel Hens; Giovanni Gabutti; Angel Gil; Bayad Nozad; Grazina Mirinaviciute; Elmira Flem; Audrey Souverain; Thomas Verstraeten; Susanne Hartwig
Journal:  BMC Infect Dis       Date:  2017-05-18       Impact factor: 3.090

7.  Trends in herpes zoster epidemiology in Germany based on primary care sentinel surveillance data, 2005-2016.

Authors:  Beate Zoch-Lesniak; Kristin Tolksdorf; Anette Siedler
Journal:  Hum Vaccin Immunother       Date:  2018-03-26       Impact factor: 3.452

Review 8.  Postherpetic neuralgia in the elderly.

Authors:  R W Johnson; J McElhaney
Journal:  Int J Clin Pract       Date:  2009-09       Impact factor: 2.503

Review 9.  Similar herpes zoster incidence across Europe: results from a systematic literature review.

Authors:  Sybil Pinchinat; Ana M Cebrián-Cuenca; Hélène Bricout; Robert W Johnson
Journal:  BMC Infect Dis       Date:  2013-04-10       Impact factor: 3.090

Review 10.  Systematic review of incidence and complications of herpes zoster: towards a global perspective.

Authors:  Kosuke Kawai; Berhanu G Gebremeskel; Camilo J Acosta
Journal:  BMJ Open       Date:  2014-06-10       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.